Psychoeducation in Patients Who Diagnosed With Schizophrenia

Quality of Life Clinical Trial

Official title:

The Effect of Group Psychoeducation That Focused on Social Skills Development Applied to Patients Who Diagnosed With Schizophrenia on Treatment Compliance, Quality of Life and Well-being

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04280835
• Other study ID #: MKTatu
• Status: Completed
• Phase: N/A
• Start date: January 1, 2019
• Est. completion date: June 30, 2019

Study information

• Verified date: February 2020
• Source: Gazi University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

People with schizophrenia are faced with social problems such as repeated hospitalizations, stigma with lack of social skills, unemployment, lack of necessary and adequate health care and education due to lack of adequate care in the community they live in. It is known that psychoeducation practices aimed at developing social skills in schizophrenia give patients new skills and these skills continue for many years. This study aimed to determine the effect of group psychoeducation that focused on social skill development on treatment adaptation, quality of life and well-being in schizophrenia patients and the interaction between these variables over time.

Description:

The aim is to determine the effect of group psychoeducation that focused on social skill development on treatment adaptation, quality of life and well-being in schizophrenia patients and the interaction between these variables over time.

The study was conducted with 42 schizophrenia patients (n=21 intervention group; n=21 control group) using a quasi-experimental research design. Patients were evaluated using a pre-test, post-test, monitoring test, "Medication Adherence Rating Scale (MARS)", "Quality of Life Scale for Schizophrenia (QLSS)" and "Flourishing Scale" (FS). The measurements were taken 3 times: pre test, post-test and 3-months post-test.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 42
• Est. completion date: June 30, 2019
• Est. primary completion date: March 30, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 61 Years

Eligibility

Inclusion Criteria:

• Volunteering

• Being 18 and over being literate

• Having been diagnosed with schizophrenia for at least three months

• Taking oral antipsychotics

• Being in remission.

Exclusion Criteria:

• Being in an acute period of exacerbation

• Actively using alcohol or psychoactive substances

• Having mental retardation or dementia

• Having another psychiatric illness that makes it impossible to cooperate.

Related Conditions & MeSH terms

• Compliance, Treatment
• Quality of Life
• Schizophrenia
• Well-Being

Intervention

Behavioral:
• Group Psychoeducation that Focused on Social Skill Development
Psychoeducation Program consists of; Preparatory Session, Recognition of Schizophrenia, Evaluating the Treatment of Schizophrenia, Stress and Coping with Stress, Improving Communication Skills, Improving Problem-solving Skills, Improving Interpersonal relationships and social activities and Evaluating Session.The sessions were held in the form of PowerPoint presentations. In the psychoeducation program, lecture, question-answer, homework, sharing experiences, group discussion, repetition, video presentation, summarization, reinforcer, and role-playing techniques were used. The day before each session, patients were phoned and reminded of the time of the session. At the end of each session, the content of the subject is given as hard copy and cookies, tea and coffee were served.

Locations

Country	Name	City	State
Turkey	Merve Kizilirmak Tatu	Ankara

Sponsors (1)

Lead Sponsor	Collaborator
Gazi University

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Quality of Life Scale for Schizophrenia (QLSS)	It evaluates the quality of life of schizophrenic patients receiving maintenance treatment. QLSS provides information about ongoing symptoms and functionality. It is a 7-degree Likert type scale applied in a semi-structured interview format. It consists of a total of four sub-dimensions and 21 questions in the form of interpersonal relationships, professional role, psychic findings and daily item use-activities. The total score of all subscales gives the total score (0-126) of quality of life.	Change from baseline to 8 weeks (also assessed at 20 weeks post-baseline)
Primary	Medication Adherence Rating Scale (MARS)	The scale assesses the patient's compliance behaviors and attitude to treatment. The scale consists of 10 questions to answer in the form of Yes/No (between 1-7 were poor in compliance with treatment and those with scores between 8-10 were high).	Change from baseline to 8 weeks (also assessed at 20 weeks post-baseline)
Primary	Flourishing Scale (FS)	It is a self-assessment scale measures an individual's level of well-being. It consists of eight items and each item is scored 1-7 points. The total score range from 8-56 points. The more the score from the scale increases the more the well-being increases.	Change from baseline to 8 weeks (also assessed at 20 weeks post-baseline)